# US 2015/0148537 A1 · Process for reducing contaminating michael acceptor levels in oxycodone and other compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148537 A1
- Document ID: US20150148537A1
- Status: Published application
- Kind: A1
- Application number: 14/586,239
- Filed: 2014-12-30
- Published: 2015-05-28
- Earliest claimed: 2005-11-22
- Assignees: Controlled Chemicals, Inc.
- Applicants: Controlled Chemicals, Inc.
- Inventors: Jules A. Shafer; Vladislav V. Telyatnikov; Hao Wang
- Web page: https://patentgrep.com/patent/US20150148537A1

## CPC

- A23L 5/27: {by chemical treatment, by adsorption or by absorption}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- C07D 489/02: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
- C07D 489/08: Oxygen atom
- G01N 30/74: Optical detectors {(measurement of intensity, velocity, spectral content, polarisation, or phase of infrared, visible or ultraviolet light G01J)}
- G01N 33/02: Food
- G01N 33/15: Medicinal preparations {; Physical properties thereof, e.g. dissolubility}
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- G01N 2030/027: {Liquid chromatography}
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention relates to processes for removal of Michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors and the resulting thiol-Michael adducts. Certain embodiments of the present invention enable quantification and/or removal of Michael acceptors and/or Michael acceptor precursors.

## Claims

### Claim at position 1

1-67. (canceled)

### Claim 68

A process for preparing a processed composition containing a pharmaceutical agent by removing a Michael acceptor contaminant from a composition containing a pharmaceutical agent to provide a processed composition comprising a reduced Michael acceptor content of less than 200 ppm which may be internalized by a living organism;
the method comprising the steps of:
treating the composition containing the Michael acceptor, or salt thereof, with a thiol-containing compound at a thiol and hydrogen ion concentration selected to yield the reduction in Michael acceptor as determined by the equilibrium expression:
[TM]/[M]=KR[T]t/(1+KSH/[H+])
wherein [TM] is concentration of thiol-Michael adduct, [M] is the concentration of Michael acceptor, [T]t is the total concentration of thiol-containing compound, [H+] is hydrogen ion concentration, KR is the equilibrium constant for the reaction, KSH is the acid dissociation constant for the thiol-containing compound;
wherein the thiol-containing compound reacts with at least one Michael acceptor or salt thereof to provide a thiol-Michael adduct or salt thereof; and
separating the resulting thiol-Michael adduct or salt thereof from the composition by one or any combination of selective precipitation or extraction of the composition in order to provide a processed composition comprising a reduced Michael acceptor content of less than 200 ppm which may be internalized by a living organism;
wherein the Michael acceptor is an α,β-unsaturated carbonyl derivative or an α,β-unsaturated nitrile.

### Claim 69

A process for preparing a processed composition containing a pharmaceutical agent by removing a Michael acceptor hydrate contaminant from a composition containing a pharmaceutical agent to provide a processed composition comprising a reduced Michael acceptor content of less than 200 ppm which may be internalized by a living organism;
the method comprising the steps of:
converting the Michael acceptor hydrate, or salt thereof, with an acidic catalyst to a Michael acceptor, or salt thereof;
reacting the composition containing the Michael acceptor, or salt thereof, with a thiol-containing compound at a thiol and hydrogen ion concentration selected to yield the reduction in Michael acceptor as determined by the equilibrium expression:
[TM]/[M]=KR[T]t/(1+KSH/[H+])
wherein [TM] is concentration of thiol-Michael adduct, [M] is the concentration of Michael acceptor, [T]t is the total concentration of thiol-containing compound, [H+] is hydrogen ion concentration, KR is the equilibrium constant for the reaction, KSH is the acid dissociation constant for the thiol-containing compound;
wherein the thiol-containing compound reacts with at least one Michael acceptor or salt thereof to form a thiol-Michael adduct or salt thereof; and
separating the thiol-Michael adduct or salt thereof from the composition by one or any combination of selective precipitation or extraction of the composition in order to provide a processed composition comprising a reduced Michael acceptor content of less than 200 ppm which may be internalized by a living organism;
wherein the Michael acceptor is an α,β-unsaturated carbonyl derivative or an α,β-unsaturated nitrile.

### Claim 70 (depends on 68)

The process of claim 68, wherein the thiol-containing compound is selected from the group consisting of sodium thioglycolate, sodium 2-mercapto ethanesulfonate, cysteine, homocysteine, cysteine hydrochloride, L-cysteine hydrochloride, N-acetyl-L-cysteine, N-dansyl-L-cysteine, 5-mercapto-2-nitro-benzoic acid, thioglycolic acid, 2-mercaptoethanesulfonic acid, glutathione, mercaptosuccinic acid, thioglycerol, 2-aminoethanethiol, ethanedithiol, dithiolthreitol, reduced lipoic acid, and salts thereof; or the thiol-containing compound is immobilized on solid support; or the thiol-containing compound is thiol functionalized silica gel.

### Claim 71 (depends on 68)

The process of claim 68, wherein after providing the thiol-Michael adduct, the process comprises extracting the pharmaceutical agent.

### Claim 72 (depends on 68)

The process of claim 68, wherein after providing the thiol-Michael adduct, the process comprises precipitating the pharmaceutical agent.

### Claim 73 (depends on 68)

The process of claim 68, wherein the process results in a processed composition wherein no single Michael acceptor or salt thereof is present in an amount exceeding 25 ppm.

### Claim 74 (depends on 68)

The process of claim 68, wherein the process results in a processed composition wherein no single Michael acceptor or salt thereof is present in an amount exceeding 10 ppm.

### Claim 75 (depends on 68)

The process of claim 68, wherein the process results in a processed composition wherein no single Michael acceptor or salt thereof is present in an amount exceeding 5 ppm.

### Claim 76 (depends on 68)

The process of claim 68, wherein the process results in a processed composition wherein no single thiol-Michael adduct or salt thereof is present in an amount exceeding 25 ppm.

### Claim 77 (depends on 69)

The process of claim 69, wherein the process results in a composition wherein the Michael acceptor hydrate or salt thereof is present in an amount of less than 100 ppm.

### Claim 78 (depends on 68)

The process of claim 68, wherein the Michael acceptor or salt thereof is removed from the composition by a factor of at least 5.

### Claim 79 (depends on 68)

The process of claim 68, wherein the process further comprises quantifying the Michael acceptor content of the processed composition by treating the processed composition with a thiol-containing compound to provide a thiol-Michael adduct, and measuring the amount of the thiol-Michael adduct.

### Claim 80 (depends on 68)

The process of claim 68, wherein the thiol-Michael adduct is a soluble thiol-Michael adduct.

### Claim 81 (depends on 68)

The process of claim 68, wherein the Michael acceptor is an α,β-unsaturated carbonyl derivative.

### Claim 82 (depends on 81)

The process of claim 81, wherein the Michael acceptor is an α,β-unsaturated carbonyl derivative selected from the group consisting of an α,β-unsaturated ketone, an α,β-unsaturated aldehyde, an α,β-unsaturated ester, an α,β-unsaturated amide, an α,β-unsaturated substituted amide, a quinone, and a maleimide.

### Claim 83 (depends on 82)

The process of claim 82, wherein the α,β-unsaturated carbonyl derivative is an α,β-unsaturated ketone.
